H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Oric Pharmaceuticals today and set a price target of $23.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Robert Burns has given his Buy rating due to a combination of factors that highlight the promising potential of ORIC-944. The recent dose exploration results for ORIC-944, in combination with apalutamide or darolutamide, have shown significant efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with androgen receptor pathway inhibitors. The combination has demonstrated deep reductions in prostate-specific antigen levels, with a notable number of patients achieving significant PSA50 and PSA90 responses.
Furthermore, the combination of ORIC-944 with an ARi appears to be less toxic compared to similar treatments, enhancing its appeal as a potential best-in-class agent. The ongoing dose optimization and the expected data from the first quarter of 2026 will further inform the development of this treatment. Based on these promising results and the increased probability of approval, Burns has raised the price target for ORIC Pharmaceuticals to $23, reinforcing the Buy rating.
In another report released today, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $15.00 price target.